ADMA
ADMA Biologics·NASDAQ
--
--(--)
--
--(--)
ADMA fundamentals
ADMA Biologics (ADMA) released its earnings on Feb 25, 2026: revenue was 139.16M (YoY +18.39%), missed estimates; EPS was 0.2132 (YoY +51.31%), beat estimates.
Revenue / YoY
139.16M
+18.39%
EPS / YoY
0.2132
+51.31%
Report date
Feb 25, 2026
ADMA Earnings Call Summary for Q4,2025
- Revenue Growth: 20% YoY to $510 million, with ASCENIV contributing 51% of revenue.
- Gross Margin Expansion: 57.4% in 2025, targeting 63.8%+ in 2026.
- Supply Chain Strength: >280 plasma centers secured, third-party supply agreements exceeding expectations.
- Pipeline Momentum: SG-001 pre-IND submission planned for 2026, targeting $300-500 million peak revenue.
- Financial Guidance: 2026 revenue >$635 million, EBITDA >$360 million,2027 revenue >$775 million, EBITDA >$455 million.
EPS
Actual | -0.26 | -0.23 | -0.19 | -0.2 | -0.16 | -0.15 | -0.13 | -0.09 | -0.13 | -0.07 | -0.08 | -0.06 | -0.03 | -0.0176 | 0.01 | -0.08 | 0.0891 | 0.1418 | 0.163 | 0.1409 | 0.1361 | 0.1473 | 0.1601 | 0.2132 | |||||||||
Forecast | -0.1142 | -0.157 | -0.1867 | -0.165 | -0.1657 | -0.1525 | -0.1383 | -0.0927 | -0.085 | -0.08 | -0.0775 | -0.07 | -0.0425 | -0.025 | -0.0075 | 0.025 | 0.055 | 0.08 | 0.13 | 0.15 | 0.1533 | 0.1367 | 0.1463 | 0.185 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -127.67% | -46.50% | -1.77% | -21.21% | +3.44% | +1.64% | +6.00% | +2.91% | -52.94% | +12.50% | -3.23% | +14.29% | +29.41% | +29.60% | +233.33% | -420.00% | +62.00% | +77.25% | +25.38% | -6.07% | -11.22% | +7.75% | +9.43% | +15.24% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.20M | 7.79M | 10.28M | 13.96M | 16.05M | 17.83M | 20.68M | 26.38M | 29.10M | 33.91M | 41.09M | 49.98M | 56.91M | 60.10M | 67.30M | 73.90M | 81.88M | 107.19M | 119.84M | 117.55M | 114.80M | 121.98M | 134.22M | 139.16M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | 11.34M | 10.57M | 9.96M | 12.85M | 14.58M | 16.42M | 18.70M | 21.76M | 25.90M | 31.81M | 34.48M | 46.35M | 51.26M | 55.50M | 62.13M | 72.13M | 77.28M | 86.42M | 105.81M | 112.77M | 116.41M | 121.77M | 131.90M | 139.60M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -10.06% | -26.34% | +3.15% | +8.60% | +10.09% | +8.62% | +10.61% | +21.26% | +12.37% | +6.58% | +19.16% | +7.82% | +11.03% | +8.29% | +8.33% | +2.47% | +5.95% | +24.03% | +13.25% | +4.24% | -1.38% | +0.18% | +1.76% | -0.31% |
Earnings Call
You can ask Aime
Did ADMA Biologics beat or miss consensus estimates last quarter?What factors drove the changes in ADMA Biologics's revenue and profit?What were the key takeaways from ADMA Biologics’s earnings call?What guidance did ADMA Biologics's management provide for the next earnings period?What does ADMA Biologics do and what are its main business segments?What is ADMA Biologics's gross profit margin?What were the key takeaways from ADMA Biologics's earnings call?What is the market's earnings forecast for ADMA Biologics next quarter?
